BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cardior Pharmaceuticals GmbH readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Cardior Pharmaceuticals GmbH's dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06979375-598@assetmemo.bio
DTSTAMP:20261121T005949Z
DTSTART;VALUE=DATE:20270516
DTEND;VALUE=DATE:20270517
SUMMARY:CDR132L: Phase 2 readout est. (NCT06979375)
DESCRIPTION:CDR132L\, phase 2\, Heart Failure.\nStudy: A Research Study Com
 paring CDR132L With Placebo on the Structure and Function of the Heart in 
 People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction an
 d Left Ventricular Hypertrophy\nEstimated primary completion: 16 May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cdr132l#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06979375
URL:https://assetmemo.bio/drug/cdr132l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979362-598@assetmemo.bio
DTSTAMP:20261121T005949Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:CDR132L: Phase 2 readout est. (NCT06979362)
DESCRIPTION:CDR132L\, phase 2\, Heart Failure.\nStudy: A Research Study Com
 paring Different Doses of CDR132L With Placebo on the Structure and Functi
 on of the Heart in People With Heart Failure With Preserved Ejection Fract
 ion and Left Ventricular Hypertrophy\nEstimated primary completion: 16 Nov
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cdr132l#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979
 362
URL:https://assetmemo.bio/drug/cdr132l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
